Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOURCE: Tezepelumab in OCS-dependent asthma
NCT03406078Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2018
- Primary completion
- Sep 2020
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 3 trial of tezepelumab in asthma, sponsored by AstraZeneca. Started Mar 2018; status: completed.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03406078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03406078.